This website is being migrated. In case you don't find the information you are looking for, the old website can be found here. Thank you for reporting any anomalies to communication@ill.eu.

Infos

180724_Galectin.png
24 juillet 2018 Key binding characteristics of a sugar-binding protein associated with heart disease and breast cancer defined for the first time, guiding future drug development
Key binding characteristics of a sugar-binding protein associated with heart disease and breast cancer defined for the first time, guiding future drug developmentResearchers pinpoint hydrogen-bonding interactions in the C-terminal carbohydrate recognition domain of galectin-3 (galectin-3C) for the first time using neutron crystallographyThese detailed observations will inform future drug design f…
180709_Space technologies_ILL_3x2_rvb.jpg
9 juillet 2018 Big science and industry join forces to innovate new space technologies
9th July 2018: Grenoble, France  – the Institut Laue-Langevin (ILL) and European Synchrotron Radiation Facility (ESRF) team up with leading European space companies OHB System AG and MT Aerospace AG to tackle industry challenges. They join forces to advance the characterisation of aerospace materials and make fabrication processes more efficient by probing matter with x-rays and neutrons.Space ex…